Bevacizumab efficacy in treatment of brain radiation necrosis
https://doi.org/10.33667/2078-5631-2019-1-10(385)-15-21
Abstract
Radiation therapy (RT) plays an important role in treatment of primary and metastatic CNS tumors and some non-neopiastic conditions (arteriovenous malformations, trigeminal neuralgia). Radiation necrosis (RN) is a common adverse effect of RT. Until recently steroid therapy was used as a main treatment regimen for RN. Mechanisms of RN development are not clear; however, it was shown that vascular endothelial growth factor (VEGF) plays a critical role in its formation. A number of surveys showed efficacy of bevacizumab as an anti-VEGF agent in treatment of RN. Radiation necrosis pathogenesis, diagnostics and treatment are summarized in this review.
About the Authors
O. V. Absalyamova
National Medical Research Centre for Neurosurgery n.a. N. N. Burdenko
Russian Federation
G. L. Kobiakov
National Medical Research Centre for Neurosurgery n.a. N. N. Burdenko
Russian Federation
S. L. Gutorov
National Medical Research Centre of Oncology n.a. N. N. Blokhin
Russian Federation
E. R. Vetlova
National Medical Research Centre for Neurosurgery n.a. N. N. Burdenko
Russian Federation
S. V. Zolotova
National Medical Research Centre for Neurosurgery n.a. N. N. Burdenko
Russian Federation
N. V. Arutyunov
Ramsay Diagnostics Rus
Russian Federation
M. V. Inozemtseva
National Medical Research Centre for Neurosurgery n.a. N. N. Burdenko
Russian Federation
N. G. Kobiakov
Moscow State University n.a. M. V. Lomonosov
Russian Federation
For citations:
Absalyamova O.V.,
Kobiakov G.L.,
Gutorov S.L.,
Vetlova E.R.,
Zolotova S.V.,
Arutyunov N.V.,
Inozemtseva M.V.,
Kobiakov N.G.
Bevacizumab efficacy in treatment of brain radiation necrosis. Medical alphabet. 2019;1(10):15-21.
(In Russ.)
https://doi.org/10.33667/2078-5631-2019-1-10(385)-15-21
Views:
1344